Overview

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy of switching to a different molecular target (from TNF to IL6) versus cycling to a second TNF inhibitor in patients with active RA, who have not adequately responded to a previous treatment with a first anti-TNF.
Phase:
Phase 4
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Treatments:
Adalimumab
Antibodies, Monoclonal
Certolizumab Pegol
Etanercept
Golimumab
Infliximab